Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide - Implications for islet amyloid formation

被引:82
作者
Park, K [1 ]
Verchere, CB [1 ]
机构
[1] Univ British Columbia, British Columbia Res Inst Childrens & Womens Hlth, Dept Pathol & Lab Med, Vancouver, BC V5Z 4H4, Canada
关键词
D O I
10.1074/jbc.M008423200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Islet amyloid deposits are a characteristic pathologic lesion of the pancreas in type 2 diabetes and are composed primarily of the islet beta cell peptide islet amyloid polypeptide (IAPP or amylin) as well as the basement membrane heparan sulfate proteoglycan perlecan. Impaired processing of the IAPP precursor has been implicated in the mechanism of islet amyloid formation. The Nand C-terminal cleavage sites where pro-LAPP is processed by prohormone convertases contain a series of basic amino acid residues that we hypothesized may interact with heparan sulfate proteoglycans. This possibility was tested using affinity chromatography by applying synthetic fragments of pro-IAPP to heparin-agarose and heparan sulfate-Sepharose. An N-terminal human pro-IAPP fragment (residues 1-30) was retained by both heparin-agarose and heparan sulfate-Sepharose, eluting at 0.18 M NaCl at pH 7.5. Substitution of alanine residues for two basic residues in the N-terminal cleavage site abolished heparin and heparan sulfate binding activity. At pH 5.5, the affinity of the wild-type peptide for heparin/heparan sulfate was increased, implying a role far histidine residues at positions 6 and 28 of pro-IAPP. A C-terminal pro-IAPP fragment (residues 41-67) had no specific affinity for either heparin or heparan sulfate, and the N- or C-terminal fragments had only weak affinity for chondroitin sulfate. These data suggest that monomeric N-terminal human pro-IAPP contains a heparin binding domain that is lost during normal processing of pro-IAPP.
引用
收藏
页码:16611 / 16616
页数:6
相关论文
共 53 条
[1]   The heparin heparan sulfate-binding site on apo serum amyloid A - Implications for the therapeutic intervention of amyloidosis [J].
Ancsin, JB ;
Kisilevsky, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (11) :7172-7181
[2]  
ANCSIN JB, 2001, IN PRESS METHODS MOL
[3]   RECEPTOR-BINDING AND HEPARIN-BINDING DOMAINS OF BASIC FIBROBLAST GROWTH-FACTOR [J].
BAIRD, A ;
SCHUBERT, D ;
LING, N ;
GUILLEMIN, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (07) :2324-2328
[4]   BINDING OF A HIGH REACTIVE HEPARIN TO HUMAN APOLIPOPROTEIN-E - IDENTIFICATION OF 2 HEPARIN-BINDING DOMAINS [J].
CARDIN, AD ;
HIROSE, N ;
BLANKENSHIP, DT ;
JACKSON, RL ;
HARMONY, JAK ;
SPARROW, DA ;
SPARROW, JT .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1986, 134 (02) :783-789
[5]   MOLECULAR MODELING OF PROTEIN-GLYCOSAMINOGLYCAN INTERACTIONS [J].
CARDIN, AD ;
WEINTRAUB, HJR .
ARTERIOSCLEROSIS, 1989, 9 (01) :21-32
[6]   Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation [J].
Castillo, GM ;
Cummings, JA ;
Yang, WH ;
Judge, ME ;
Sheardown, MJ ;
Rimvall, K ;
Hansen, JB ;
Snow, AD .
DIABETES, 1998, 47 (04) :612-620
[7]  
Charge SBP, 1996, J PATHOL, V179, P443
[8]   ISLET AMYLOID POLYPEPTIDE IN DIABETIC AND NONDIABETIC PIMA-INDIANS [J].
CLARK, A ;
SAAD, MF ;
NEZZER, T ;
UREN, C ;
KNOWLER, WC ;
BENNETT, PH ;
TURNER, RC .
DIABETOLOGIA, 1990, 33 (05) :285-289
[9]  
CLARK A, 1989, CELL TISSUE RES, V257, P179
[10]  
Clarris HJ, 1997, J NEUROCHEM, V68, P1164